CN1852925A - 人源化免疫球蛋白基因座 - Google Patents

人源化免疫球蛋白基因座 Download PDF

Info

Publication number
CN1852925A
CN1852925A CNA2004800261928A CN200480026192A CN1852925A CN 1852925 A CN1852925 A CN 1852925A CN A2004800261928 A CNA2004800261928 A CN A2004800261928A CN 200480026192 A CN200480026192 A CN 200480026192A CN 1852925 A CN1852925 A CN 1852925A
Authority
CN
China
Prior art keywords
gene
sequence
nucleic acid
human
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800261928A
Other languages
English (en)
Chinese (zh)
Inventor
R·比罗
W·范肖滕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Therapeutic Human Polyclonals Inc
Original Assignee
Therapeutic Human Polyclonals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeutic Human Polyclonals Inc filed Critical Therapeutic Human Polyclonals Inc
Priority to CN201210390234.2A priority Critical patent/CN103205436B/zh
Publication of CN1852925A publication Critical patent/CN1852925A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/107—Rabbit
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNA2004800261928A 2003-07-15 2004-07-15 人源化免疫球蛋白基因座 Pending CN1852925A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201210390234.2A CN103205436B (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48773303P 2003-07-15 2003-07-15
US60/487,733 2003-07-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201210390234.2A Division CN103205436B (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座

Publications (1)

Publication Number Publication Date
CN1852925A true CN1852925A (zh) 2006-10-25

Family

ID=34079388

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2004800261928A Pending CN1852925A (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座
CN201210390234.2A Expired - Lifetime CN103205436B (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201210390234.2A Expired - Lifetime CN103205436B (zh) 2003-07-15 2004-07-15 人源化免疫球蛋白基因座

Country Status (10)

Country Link
US (4) US7585668B2 (enExample)
EP (1) EP1644417B1 (enExample)
JP (2) JP2007537704A (enExample)
CN (2) CN1852925A (enExample)
AU (1) AU2004257292A1 (enExample)
CA (1) CA2532117C (enExample)
ES (1) ES2473596T3 (enExample)
IL (1) IL172885A0 (enExample)
MX (1) MXPA06000562A (enExample)
WO (1) WO2005007696A2 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104202971A (zh) * 2012-02-01 2014-12-10 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物
CN105189545A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
CN105188357A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 表达限制的免疫球蛋白轻链库的小鼠
CN106414717A (zh) * 2014-05-02 2017-02-15 凯奥目生物科学株式会社 产生人抗体的细胞
US9969814B2 (en) 2010-02-08 2018-05-15 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
US10130081B2 (en) 2011-08-05 2018-11-20 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
CN109996441A (zh) * 2016-11-04 2019-07-09 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
CN110540996A (zh) * 2019-08-29 2019-12-06 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用
CN112690250A (zh) * 2008-12-18 2021-04-23 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
US20100034782A1 (en) * 2006-05-31 2010-02-11 Nader Najafian Methods of Using Anti-Thymocyte Globulin and Related Agents
US20090053210A1 (en) 2006-09-01 2009-02-26 Roland Buelow Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
KR101703299B1 (ko) * 2007-06-01 2017-02-06 오픈 모노클로날 테크놀로지, 인코포레이티드 내생적 면역글로불린 유전자를 억제하고 트랜스제닉 인간 이디오타입 항체를 생산하기 위한 방법 및 조성물
JP5588866B2 (ja) * 2007-08-10 2014-09-10 メダレックス エル．エル．シー． Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例
KR101563017B1 (ko) * 2007-08-14 2015-10-23 오리겐 테라퓨틱스 인코포레이티드 불활성화된 내인성 유전자좌를 갖는 트랜스제닉 닭
EP2108696A1 (en) * 2008-04-10 2009-10-14 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Cis-acting diversification activator and method for selective diversification of nucleic acids
DK3241435T3 (da) * 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
EP2464220A4 (en) 2009-08-13 2014-05-07 Crystal Bioscience Inc Transgenic animal for the production of antibodies with minimal complementarity-determining regions
US8865462B2 (en) * 2010-01-20 2014-10-21 Crystal Bioscience Inc. Sustained culture of avian gonocytes
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL3248462T3 (pl) * 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
MY195217A (en) 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
EP2601298B1 (en) 2010-08-02 2016-11-30 Regeneron Pharmaceuticals, Inc. Mice that make binding proteins comprising vl domains
CN102250239B (zh) * 2011-06-13 2013-04-17 中国农业科学院哈尔滨兽医研究所 一种与兔出血症病毒vp60蛋白相结合的蛋白及其应用
AU2012311286B2 (en) * 2011-09-19 2018-07-26 Kymab Limited Antibodies, variable domains and chains tailored for human use
EP4074833A1 (en) 2011-10-17 2022-10-19 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
SMT201900296T1 (it) 2011-12-20 2019-07-11 Regeneron Pharma Topi di catena leggera umanizzata
EP2794662A1 (en) 2011-12-22 2014-10-29 F.Hoffmann-La Roche Ag Full length antibody display system for eukaryotic cells and its use
HUE037659T2 (hu) 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
US9801362B2 (en) 2012-03-16 2017-10-31 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
NZ703973A (en) * 2012-08-03 2018-04-27 Sab Llc Complex chromosome engineering for production of human antibodies in transgenic animals
RS57582B1 (sr) 2013-02-20 2018-11-30 Regeneron Pharma Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
SG10201808083VA (en) 2014-03-21 2018-10-30 Regeneron Pharma Vl antigen binding proteins exhibiting distinct binding characteristics
AU2015230938C1 (en) 2014-03-21 2021-10-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
HK1258306A1 (zh) * 2015-10-29 2019-11-08 F. Hoffmann-La Roche Ag 具有共同轻链的转基因兔
US10879744B2 (en) 2016-12-05 2020-12-29 Koninklijke Philips N.V. Foreign object detection in a wireless power transfer system
CA3050715A1 (en) * 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
WO2019129677A1 (en) 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Anti-vegf antibodies and methods of use
ES3076179T3 (en) 2018-03-21 2026-08-12 Crystal Bioscience Inc Transgenic chicken that produces human antibodies
EP3990492A1 (en) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
EP4075965A1 (en) * 2019-12-18 2022-10-26 Bristol-Myers Squibb Company Bcr transgenic mice with a common leader sequence
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
CN114854901B (zh) * 2022-06-22 2025-11-07 华南农业大学 与苦瓜全雌性状共分离的分子标记、引物及其应用
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
WO2026132145A1 (en) 2024-12-20 2026-06-25 F. Hoffmann-La Roche Ag Antibodies binding to tn-muc-1

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69130702T2 (de) 1990-07-10 1999-05-27 Nkk Corp., Tokio/Tokyo Geflügelspezifischen immunglobulin g produzierende hybridomas
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
EP0583980A1 (en) 1992-08-20 1994-02-23 Eli Lilly And Company Method for generating monoclonal antibodies from rabbits
AU7326796A (en) 1995-10-30 1997-05-22 Spectral Diagnostics Inc. Stable chicken b-cell line and method of use thereof
DE60023451T2 (de) 1999-02-05 2006-07-20 Therapeutic Human Polyclonals, Inc., Mountain View Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper
EP1190042A2 (en) 1999-06-04 2002-03-27 Tranxenogen, Inc. Methods for manipulating the avian genome
WO2001019394A2 (en) 1999-09-15 2001-03-22 Therapeutic Human Polyclonals, Inc. Immunotherapy with substantially human polyclonal antibody preparations purified from genetically engineered birds
IL154751A0 (en) * 2000-08-03 2003-10-31 Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals
ATE430756T1 (de) 2002-06-26 2009-05-15 Transgenrx Inc Genregulation in transgenen tieren unter verwendung eines vektors auf transposonbasis
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
WO2006021962A2 (en) 2004-08-27 2006-03-02 Medic4All A.G System of medical information through mobile device
US20110077965A1 (en) 2009-09-25 2011-03-31 Cerner Innovation, Inc. Processing event information of various sources
US20120306653A1 (en) 2011-06-02 2012-12-06 Nokia Siemens Networks Oy Medical sensor
US20130021154A1 (en) 2011-07-21 2013-01-24 Solomon Clifford T Medical parameters notification system

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112690250A (zh) * 2008-12-18 2021-04-23 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
US9969814B2 (en) 2010-02-08 2018-05-15 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
US12628801B2 (en) 2011-08-05 2026-05-19 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
US11357217B2 (en) 2011-08-05 2022-06-14 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
US10130081B2 (en) 2011-08-05 2018-11-20 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
CN104202971B (zh) * 2012-02-01 2016-07-06 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
CN106117364A (zh) * 2012-02-01 2016-11-16 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
CN106117364B (zh) * 2012-02-01 2021-08-31 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物的制备方法
CN104202971A (zh) * 2012-02-01 2014-12-10 瑞泽恩制药公司 表达包含vl结构域的重链的人源化啮齿动物
CN105188357B (zh) * 2013-03-13 2018-04-24 瑞泽恩制药公司 表达限制的免疫球蛋白轻链库的小鼠
CN105188357A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 表达限制的免疫球蛋白轻链库的小鼠
CN105189545A (zh) * 2013-03-13 2015-12-23 瑞泽恩制药公司 常见轻链小鼠
CN106414717A (zh) * 2014-05-02 2017-02-15 凯奥目生物科学株式会社 产生人抗体的细胞
CN109996441A (zh) * 2016-11-04 2019-07-09 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物
CN110540996A (zh) * 2019-08-29 2019-12-06 华中农业大学 一种克氏原螯虾i型溶菌酶gLysi2基因、其编码的gLysi2蛋白及其应用

Also Published As

Publication number Publication date
JP6017763B2 (ja) 2016-11-02
IL172885A0 (en) 2006-06-11
EP1644417B1 (en) 2014-04-30
USRE47131E1 (en) 2018-11-20
AU2004257292A1 (en) 2005-01-27
US20100205682A1 (en) 2010-08-12
JP2011182801A (ja) 2011-09-22
WO2005007696A2 (en) 2005-01-27
US8652842B2 (en) 2014-02-18
US8410333B2 (en) 2013-04-02
JP2007537704A (ja) 2007-12-27
EP1644417A2 (en) 2006-04-12
US7585668B2 (en) 2009-09-08
MXPA06000562A (es) 2006-03-30
CA2532117C (en) 2012-07-10
WO2005007696A3 (en) 2005-11-03
ES2473596T3 (es) 2014-07-07
US20130189774A1 (en) 2013-07-25
CN103205436B (zh) 2016-05-25
CA2532117A1 (en) 2005-01-27
US20060026696A1 (en) 2006-02-02
CN103205436A (zh) 2013-07-17

Similar Documents

Publication Publication Date Title
AU2018223041B2 (en) Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
KR102266274B1 (ko) 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
KR102630357B1 (ko) 단백질 발현이 어려운 다중-부위 ssi 세포
KR102719587B1 (ko) 아데노-관련 바이러스 생산을 위한 포유동물 세포
AU2023214237A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
AU2019316556B9 (en) Methods for assessing the risk of developing progressive multifocal leukoencephalopathy caused by john cunningham virus by genetic testing
AU2016364667A1 (en) Materials and methods for treatment of Alpha-1 antitrypsin deficiency
EP1165784A2 (en) Nucleic acids including open reading frames encoding polypeptides; "orfx"
JP2003088388A (ja) 新規な全長ｃＤＮＡ
JP2003135075A (ja) 新規な全長ｃＤＮＡ
AU2017289886A1 (en) Engineered parasites for delivering protein to the central nervous system (CNS)
WO1995014772A1 (en) Gene signature
HUE034321T2 (en) Restricted immunoglobulin heavy chain mice
KR20190120170A (ko) Vhh-함유 중쇄 항체 및 이의 생산
KR102777514B1 (ko) 다중 중쇄 면역글로불린 유전자좌를 갖는 트랜스제닉 설치류 기원의 인간 항체
KR20110110030A (ko) 뇌종양의 재발 가능성 및 생존 예후 예측용 조성물 및 이를 포함하는 키트
CN113249470A (zh) 用于肺癌的体外诊断或预后的方法
KR101978399B1 (ko) 자궁내막증에 대한 진단 마커로서의 돌연변이 유전자 및 이의 용도
JP2002017375A (ja) 全長ｃＤＮＡ合成用プライマー、およびその用途
KR102364720B1 (ko) 교모세포종 진단용 바이오마커 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20061025